title: [The place of β-adrenoblockers in the treatment of cardiovascular disease in patients with chronic obstructive pulmonary disease].
abstract: Review is devoted to the place of β-adrenoblockers in the treatment of cardiovascular disease (CVD) in patients with chronic obstructive pulmonary disease (COPD). Currently, it is expedient to use cardioselective -adrenoblockers, such as bisoprolol, metoprolol succinate, carvedilol and nebivolol for the treatment of patients with CVD and COPD. Bisoprolol has the greatest (of all the cardioselective β-adrenoblockers) evidence base of data on the efficacy and safety of using in patients with COPD and CVD. While using a cardioselective β-adrenoblockers external respiration function (ERF) should be controlled. When clinical signs of worsening airway conductance appear, and adverse effects on ERF parameters are observed, β-adrenoblockers dosage should be reduced, while maintaining lower respiratory functions need to be canceled. In general, the use of cardioselective β-adrenoblockers in patients with CVD and COPD is safe, and the benefits of the drugs in this group exceed the risks of exacerbation of COPD. If possible the use of 2-agonists should be limited in patients with CVD in the treatment of COPD because of their negative impact on the cardiovascular system - the preferred use of anticholinergic drugs.
authors.forename: M E
authors.initials: ME
authors.lastname: Statsenko
authors.forename: M V
authors.initials: MV
authors.lastname: Derevianchenko
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists